Detection of ovarian cancer
AssigneeMount Sinai Hospital
InventorsEleftherios P. Diamandis, Liu-Ying Luo
Life of this patent
Estimating the term…
Abstract
A method for the diagnosis, prognosis, and monitoring of ovarian cancer in a subject by detecting hK10 in a sample from the subject, preferably a serum sample or tumor tissue extract. hK10 may be measured using a reagent that detects or binds to hK10 preferably antibodies specifically reactive with hK10 or a part thereof. Imaging methods for tumors associated with hK10 are also described using an agent that binds to hK10 which had a label for imaging the tumor.
Claims17
A method of evaluating the probability of the presence of ovarian cancer in a subject, the method comprising:
- measuring the amounts of human kallikrein 10 (hK10) in a biological sample from the subject;
- comparing the measured amounts of hK10 in the biological sample to an hK10 standard, wherein said hK10 standard is a level of hK10 obtained from a sample of a member of the group consisting of a healthy subject, a subject with normal or benign ovarian tissue, and a subject having early stage ovarian cancer, and
- identifying an increase in the amount of hK10 in the biological sample as compared to the hK10 standard, wherein said increase is indicative of the probability of the presence of malignant or pre-malignant cells of ovarian cancer.
A method of evaluating the probability of the presence of ovarian cancer in a subject, the method comprising:
- measuring the amounts of human kallikrein 10 (hK10) and at least one additional marker in a biological sample from the subject;
- comparing the measured amounts of hK10 and said additional marker in the biological sample to an hK10 standard and additional marker standard, respectively, wherein said hK10 standard and additional marker standards are levels of hK10 and the additional marker, respectively, obtained from a sample of a member of the group consisting of a healthy subject, a subject with normal or benign ovarian tissue, and a subject having early stage ovarian cancer, and
- identifying an increase in the amount of hK10 in the biological sample as compared to the hK10 standard coupled with a change in the amount of the additional marker in the biological sample as compared to the additional marker standard, wherein said increase is indicative of the probability of the presence of malignant or pre-malignant cells of ovarian cancer.
Dependencies are inferred from the claim text.